Cervical Cancer
Methodology & AI Transparency ⓘ
Cervical Cancer Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is cervical cancer? Cervical cancer is cancer that starts in the cells of the cervix.
- 2 Real-world patient consensus: Mapped to Cancer, Oncology & Supportive Care under ICD-10-CM C53.9 for Cervical Cancer clinical workups.
- 3 Typical cash cost range: Differential triage of Cervical Cancer (C53.9) utilizes radiation) paired with in Cervical Cancer (C53.9: proactive supportive symptom).
- 4 Top reported side effects / signs: Follow-up benchmark in Cervical Cancer: maintaining Complete Blood Count in Cervical Cancer (C53.9: (ANC, Hemoglobin, Platelets)) within Safe hematologic reserve (C53.9).
Ask our AI Specialists anything about Cervical Cancer
What Is Cervical Cancer?
What is cervical cancer? Cervical cancer is cancer that starts in the cells of the cervix. The cervix is part of the female reproductive system. It is the lower, narrow end of the uterus (womb), which opens into the vagina (birth canal). Cervical cancer usually develops slowly. Before cervical cells become cancer, they start to look abnormal. These cells are called "precancers." If they aren't destroyed or removed, they may become cancer cells that grow out of control and spread to other parts of your body. Screening tests for cervical cancer can help find abnormal cells so you can get treatment to prevent cervical cancer.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Cervical Cancer (C53.9) features tumor-suppressor loss enabling in Cervical Cancer (C53.9: clonal proliferation). Cross-referenced with NIH MeSH (Uterine Cervical Neoplasms), therapeutic stabilization in cancer & oncology is verified against Comprehensive Metabolic & in Cervical Cancer (C53.9: Organ Function Panel).
Common Symptoms & Clinical Signs
- • Have a weakened immune system because you: • Have a disease that harms your immune system, such as HIV
- • Take medicine to control your immune system, such as certain medicines to treat cancer or autoimmune diseases
- • Presentation of Cervical Cancer (C53.9): unintended weight loss [Cervical Cancer C53.9]
- • Secondary Cervical Cancer clinical sign: unexplained bleeding, chronic in Cervical Cancer (C53.9: hoarseness/cough, or progressive)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Cervical Cancer Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C53.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Complete Blood Count in Cervical Cancer (C53.9: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C53.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Cervical Cancer (C53.9: Organ Function Panel) | Preserved renal/hepatic clearance (C53.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pathology / Molecular in Cervical Cancer (C53.9: Genomic Staging) | Guideline-concordant surveillance (C53.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Cervical Cancer
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Dinoprostone Cervidil, Prepidil • RxCUI 597957 | Prostaglandin Analog | 93% | $1.6400 | $ 74.92 /mo |
| Cervidil (Dinoprostone) Cervidil • RxCUI 597959 | Prostaglandin Analog | 85% | $0.2300 | $ 25.06 /mo |
| Prepidil (Dinoprostone) Prepidil • RxCUI RXN-B00093359 | Prostaglandin Analog | 91% | $0.7400 | $ 61.78 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Cervical Cancer)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Monofilament suture versus braided suture thread to improve pregnancy outcomes: What a 1,025-Participant Study Found Monofilament suture did not reduce rate of pregnancy loss when compared with a braided suture. Lancet (London, England) • 2022-10-22 • Phase III Randomized Trial | N = 1,025 | 90/100 | PMID 36273481 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of controlled-release dinoprostone vaginal delivery system PROPESS administration for a maximum of 12 h was an effective and well-tolerated treatment for pregnant Japanese women post-term requiring cervical ripening. The journal of obstetrics and gynaecology research • 2021-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33094550 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of DaxibotulinumtoxinA for injection in adults with cervical This pooled analysis of two phase 3 trials demonstrates that DAXI is an effective, safe, and long-acting treatment for CD. Parkinsonism & related disorders • 2025-11-15 • Phase III Randomized Trial | N = 149 | 88/100 | PMID 40961718 ↗ |
| Pembrolizumab with chemoradiotherapy followed by pembrolizumab for stage III-IVa cervical cancer: is the ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial practice changing? The associated costs render it unattainable in the regions where burden of cervical cancer is highest. Cancer • 2025-02-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39913282 ↗ |
| New Insights on Low-Dose-Rate versus High-Dose-Rate intracavitary brachytherapy in cervical: What a 441-Participant Study Found HDR intracavitary brachytherapy with 7 Gy per fraction weekly is superior to LDR in terms of late rectal and bladder complications. Brachytherapy • 2021-01-15 • Phase III Randomized Trial | N = 441 | 87/100 | PMID 34598883 ↗ |
Cervical Cancer Patient Community & “People Like Me” Threads
Filter Cervical Cancer community threads and patient logs by age, biological sex, dosage, and treatment duration.